2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T815,The effects of small, realistic changes in physical activity and sedentary behaviour on population-level mortality are unclear. We aimed to estimate the proportion of deaths preventable by 5-min and 10-min incremental increases in moderate-to-vigorous intensity physical activity (MVPA) and 30-min and 60-min reductions in daily sedentary time. We did an individual participant data meta-analysis of prospective cohort studies. We included studies with device-measured physical activity and sedentary time. We estimated the proportion of deaths prevented (potential impact fractions; PIFs) by changes in (1) the approximately 20% least active participants (high-risk approach) and (2) all participants except the approximately 20% most active (population-based approach). We calculated PIFs from adjusted hazard ratios estimated for 5-min and 10-min increases in MVPA and 30-min and 60-min reductions in sedentary time from observed levels across the activity distribution. We included seven cohorts from Norway, Sweden, and the USA (n=40 327; 4895 deaths). Data from the UK Biobank (n=94 719; 3487 deaths) were analysed separately. A 5-min/day increase in MVPA in the least active participants might prevent 6·0% (95% CI 4·3-7·4) of all deaths. A similar increase in MVPA in all participants except the most active might prevent 10·0% (6·3-13·4) of all deaths. Reducing sedentary time by 30 min/day might prevent 3·0% (2·0-4·1) of all deaths in the high-risk approach and 7·3% (4·8-9·6) in the population-based approach. Results from the UK Biobank were of a smaller magnitude but still substantial-eg, reducing sedentary time by 30 min/day in all except the most active participants was associated with preventing 4·5% (2·8-6·1) of total deaths. Small and realistic increases in MVPA of 5 min/day might prevent up to 6% of all deaths in a high-risk approach and 10% of all deaths in population-based approach. Reducing sedentary time by 30 min/day might prevent a smaller, but still meaningful, proportion of deaths in the two risk scenarios. None.31:T972,The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer-specific mortality, and other-cause mortality. The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer-specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates.32:Tf7c, Importance The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. Objective To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. Data Sources This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. Study Selection For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. Data Extraction and Synthesis Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. Main Outcomes and Measures The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer–specific mortality, and other-cause mortality. Results The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer–specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. Conclusions and Relevance The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Individual Participant Data Meta-analysis: study design Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Individual Participant Data Meta-analysis (study design). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/study_design/Individual%20Participant%20Data%20Meta-analysis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study Designs\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Individual Participant Data Meta-analysis\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design/Individual%20Participant%20Data%20Meta-analysis\"}]}}"}}]],["$","$L2f",null,{"title":"Individual Participant Data Meta-analysis: Research & Clinical Takeaways","description":"Browse Individual Participant Data Meta-analysis research papers with clear, practical takeaways for your clinical practice.","papers":[{"doi":"10.1016/s0140-6736(25)02219-6","pmid":"41544645","title":"Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies","journal_title":"The Lancet","journal_issn":"0140-6736","published_at":"2026-01-17T00:00:00.000Z","url":"https://doi.org/10.1016/s0140-6736(25)02219-6","source_score":988,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-18","doi":"10.1016/s0140-6736(25)02219-6","days":"7","issn":"0140-6736","rank":"3","field":"Clinical Medicine","score":"988","category":"Medicine, General & Internal","categories":["Medicine, General & Internal"],"_categories":["Medicine, General & Internal"]},"pubmed":{"doi":"10.1016/S0140-6736(25)02219-6","title":"Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies.","journal":"Lancet (London, England)","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41544645","conclusions":"","publication_date":"2026-01-17T00:00:00"},"crossref":{"DOI":"10.1016/s0140-6736(25)02219-6","URL":"https://doi.org/10.1016/s0140-6736(25)02219-6","ISSN":["0140-6736"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0140673625022196?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0140673625022196?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies"],"author":[{"given":"Ulf","family":"Ekelund","sequence":"first","affiliation":[]},{"given":"Jakob","family":"Tarp","sequence":"additional","affiliation":[]},{"given":"Ding","family":"Ding","sequence":"additional","affiliation":[]},{"given":"Miguel Adriano","family":"Sanchez-Lastra","sequence":"additional","affiliation":[]},{"given":"Knut Eirik","family":"Dalene","sequence":"additional","affiliation":[]},{"given":"Sigmund A","family":"Anderssen","sequence":"additional","affiliation":[]},{"given":"Jostein","family":"Steene-Johannessen","sequence":"additional","affiliation":[]},{"given":"Bjorge H","family":"Hansen","sequence":"additional","affiliation":[]},{"given":"Bente","family":"Morseth","sequence":"additional","affiliation":[]},{"given":"Laila A","family":"Hopstock","sequence":"additional","affiliation":[]},{"given":"Edvard","family":"Sagelv","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Nordström","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Nordström","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Hagströmer","sequence":"additional","affiliation":[]},{"given":"Ing-Mari","family":"Dohrn","sequence":"additional","affiliation":[]},{"given":"Keith M","family":"Diaz","sequence":"additional","affiliation":[]},{"given":"Steven","family":"Hooker","sequence":"additional","affiliation":[]},{"given":"Virginia J","family":"Howard","sequence":"additional","affiliation":[]},{"given":"I-Min","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Morten W","family":"Fagerland","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2026-01-13T23:45:46Z","timestamp":1768347946000,"date-parts":[[2026,1,13]]},"indexed":{"date-time":"2026-01-20T09:09:34Z","timestamp":1768900174378,"date-parts":[[2026,1,20]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0140673625022196"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies"},{"name":"journaltitle","label":"Journal Title","value":"The Lancet"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/S0140-6736(25)02219-6"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 Published by Elsevier Ltd."}],"deposited":{"date-time":"2026-01-13T23:46:05Z","timestamp":1768347965000,"date-parts":[[2026,1,13]]},"issn-type":[{"type":"print","value":"0140-6736"}],"published":{"date-parts":[[2026,1]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/S0140-6736(12)61031-9","key":"10.1016/S0140-6736(25)02219-6_bib1","year":"2012","issue":null,"author":"Lee","volume":"380","first-page":"219","unstructured":null,"article-title":"Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2020-103640","key":"10.1016/S0140-6736(25)02219-6_bib2","year":"2022","issue":null,"author":"Katzmarzyk","volume":"56","first-page":"101","unstructured":null,"article-title":"Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2214-109X(20)30211-4","key":"10.1016/S0140-6736(25)02219-6_bib3","year":"2020","issue":null,"author":"Strain","volume":"8","first-page":"e920","unstructured":null,"article-title":"Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study","journal-title":"Lancet Glob Health","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2019-101765","key":"10.1016/S0140-6736(25)02219-6_bib4","year":"2020","issue":null,"author":"Ekelund","volume":"54","first-page":"1125","unstructured":null,"article-title":"Physical activity and mortality: what is the dose response and how big is the effect?","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S0140-6736(25)02219-6_bib5","year":"2019","issue":null,"author":"Ekelund","volume":"366","first-page":null,"unstructured":null,"article-title":"Dose–response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis","journal-title":"BMJ","doi-asserted-by":null},{"DOI":"10.1038/s41591-020-1012-3","key":"10.1016/S0140-6736(25)02219-6_bib6","year":"2020","issue":null,"author":"Strain","volume":"26","first-page":"1385","unstructured":null,"article-title":"Wearable-device-measured physical activity and future health risk","journal-title":"Nat Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41591-022-02100-x","key":"10.1016/S0140-6736(25)02219-6_bib7","year":"2022","issue":null,"author":"Stamatakis","volume":"28","first-page":"2521","unstructured":null,"article-title":"Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality","journal-title":"Nat Med","doi-asserted-by":"crossref"},{"DOI":"10.1161/CIRCULATIONAHA.117.031300","key":"10.1016/S0140-6736(25)02219-6_bib8","year":"2018","issue":null,"author":"Lee","volume":"137","first-page":"203","unstructured":null,"article-title":"Accelerometer-measured physical activity and sedentary behaviour in relation to all-cause mortality: the Women's Health Study","journal-title":"Circulation","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2020-102955","key":"10.1016/S0140-6736(25)02219-6_bib9","year":"2020","issue":null,"author":"Bull","volume":"54","first-page":"1451","unstructured":null,"article-title":"World Health Organization 2020 guidelines on physical activity and sedentary behaviour","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2020-103270","key":"10.1016/S0140-6736(25)02219-6_bib10","year":"2020","issue":null,"author":"Ekelund","volume":"54","first-page":"1499","unstructured":null,"article-title":"Joint associations of accelero-meter measured physical activity and sedentary time with all-cause mortality: a harmonised meta-analysis in more than 44 000 middle-aged and older individuals","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2022-106568","key":"10.1016/S0140-6736(25)02219-6_bib11","year":"2023","issue":null,"author":"Sagelv","volume":"57","first-page":"1457","unstructured":null,"article-title":"Device-measured physical activity, sedentary time, and risk of all-cause mortality: an individual participant data analysis of four prospective cohort studies","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S0140-6736(25)02219-6_bib12","year":"2013","issue":null,"author":"Johnson","volume":"2","first-page":"161","unstructured":null,"article-title":"National health and nutrition examination survey: analytic guidelines, 1999–2010. National Center for Health Statistics","journal-title":"Vital Health Stat","doi-asserted-by":null},{"DOI":"10.1371/journal.pone.0169649","key":"10.1016/S0140-6736(25)02219-6_bib13","year":"2017","issue":null,"author":"Doherty","volume":"12","first-page":null,"unstructured":null,"article-title":"Large scale population assessment of physical activity using wrist worn accelerometers: the UK Biobank Study","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41598-018-26174-1","key":"10.1016/S0140-6736(25)02219-6_bib14","year":"2018","issue":null,"author":"Willetts","volume":"8","first-page":null,"unstructured":null,"article-title":"Statistical machine learning of sleep and physical activity phenotypes from sensor data in 96 220 UK Biobank participants","journal-title":"Sci Rep","doi-asserted-by":"crossref"},{"DOI":"10.1136/bjsports-2021-104050","key":"10.1016/S0140-6736(25)02219-6_bib15","year":"2021","issue":null,"author":"Walmsley","volume":"56","first-page":"1008","unstructured":null,"article-title":"Reallocation of time between device-measured movement behaviours and risk of incident cardiovascular disease","journal-title":"Br J Sports Med","doi-asserted-by":"crossref"},{"DOI":"10.1136/jech.2009.090274","key":"10.1016/S0140-6736(25)02219-6_bib16","year":"2010","issue":null,"author":"Barendregt","volume":"64","first-page":"209","unstructured":null,"article-title":"Categorical versus continuous risk factors and the calculation of potential impact fractions","journal-title":"J Epidemiol Community Health","doi-asserted-by":"crossref"},{"DOI":"10.1093/ije/30.3.427","key":"10.1016/S0140-6736(25)02219-6_bib17","year":"2001","issue":null,"author":"Rose","volume":"30","first-page":"427","unstructured":null,"article-title":"Sick individuals and sick populations","journal-title":"Int J Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0198587","key":"10.1016/S0140-6736(25)02219-6_bib18","year":"2018","issue":null,"author":"Duncan","volume":"13","first-page":null,"unstructured":null,"article-title":"Convergent validity of ActiGraph and actical accelerometers for estimating physical activity in adults","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1177/1536867X1101100101","key":"10.1016/S0140-6736(25)02219-6_bib19","year":"2011","issue":null,"author":"Orsini","volume":"11","first-page":"1","unstructured":null,"article-title":"A procedure to tabulate and plot results after flexible modelling of a quantitative covariate","journal-title":"Stata J","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12966-020-01009-3","key":"10.1016/S0140-6736(25)02219-6_bib20","year":"2020","issue":null,"author":"Nguyen","volume":"17","first-page":"117","unstructured":null,"article-title":"The effectiveness of sedentary behaviour interventions on sitting time and screen time in children and adults: an umbrella review of systematic reviews","journal-title":"Int J Behav Nutr Phys Act","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S0140-6736(25)02219-6_bib21","year":"2021","issue":null,"author":"Chastin","volume":"6","first-page":null,"unstructured":null,"article-title":"Interventions for reducing sedentary behaviour in community-dwelling older adults","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1371/journal.pmed.1002210","key":"10.1016/S0140-6736(25)02219-6_bib22","year":"2017","issue":null,"author":"Harris","volume":"14","first-page":null,"unstructured":null,"article-title":"Effect of a primary care walking intervention with and without nurse support on physical activity levels in 45- to 75-year olds: the Pedometer and Consultation Evaluation (PACE-UP) cluster randomised controlled trail","journal-title":"PLoS Med","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pmed.1002526","key":"10.1016/S0140-6736(25)02219-6_bib23","year":"2018","issue":null,"author":"Harris","volume":"15","first-page":null,"unstructured":null,"article-title":"Physical activity levels in adults and older adults 3–4 years after pedometer-based walking interventions: long-term follow-up of participants from two randomised controlled trials in UK primary care","journal-title":"PLoS Med","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamainternmed.2021.7755","key":"10.1016/S0140-6736(25)02219-6_bib24","year":"2022","issue":null,"author":"Saint-Maurice","volume":"182","first-page":"349","unstructured":null,"article-title":"Estimated number of deaths prevented through increased physical activity among US adults","journal-title":"JAMA Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.c221","key":"10.1016/S0140-6736(25)02219-6_bib25","year":"2010","issue":null,"author":"Riley","volume":"340","first-page":"c221","unstructured":null,"article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1093/aje/kwx246","key":"10.1016/S0140-6736(25)02219-6_bib26","year":"2017","issue":null,"author":"Fry","volume":"186","first-page":"1026","unstructured":null,"article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population","journal-title":"Am J Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1093/eurheartj/ehac613","key":"10.1016/S0140-6736(25)02219-6_bib27","year":"2022","issue":null,"author":"Dempsey","volume":"43","first-page":"4789","unstructured":null,"article-title":"Physical activity volume, intensity, and incident cardiovascular disease","journal-title":"Eur Heart J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.gaitpost.2015.11.005","key":"10.1016/S0140-6736(25)02219-6_bib28","year":"2016","issue":null,"author":"Kamada","volume":"44","first-page":"23","unstructured":null,"article-title":"Comparison of physical activity assessed using hip- and wrist-worn accelerometers","journal-title":"Gait Posture","doi-asserted-by":"crossref"},{"DOI":"10.1249/MSS.0000000000000476","key":"10.1016/S0140-6736(25)02219-6_bib29","year":"2015","issue":null,"author":"Tudor-Locke","volume":"47","first-page":"839","unstructured":null,"article-title":"Comparison of step outputs for waist and wrist accelerometer attachment sites","journal-title":"Med Sci Sports Exerc","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(21)00590-0","key":"10.1016/S0140-6736(25)02219-6_bib30","year":"2021","issue":null,"author":"Rahimi","volume":"397","first-page":"1625","unstructured":null,"article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","journal-title":"Lancet","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0140673625022196"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Lancet"],"published-print":{"date-parts":[[2026,1]]},"reference-count":30,"published-online":null,"references-count":30,"short-container-title":["The Lancet"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1016/s0140-6736(25)02219-6","is_oa":false,"title":"Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies","updated":"2026-01-15T02:17:35+00:00","published_date":"2026-01-01","best_oa_location":null}},"created_at":"2026-01-19T09:31:36.873Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"condition","value":"All-Cause Mortality","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"modality","value":"Lifestyle Intervention","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"sample_size","value":"n=40,327","value_numeric":40327},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"study_design","value":"Individual Participant Data Meta-analysis","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"warning","value":"Abstract provides estimates for 5-min MVPA and 30-min sedentary reductions; 10-min/60-min results are not detailed here.","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"warning","value":"Design label approximated; this is an IPD meta-analysis of prospective cohorts.","value_numeric":null},{"paper_doi":"10.1016/s0140-6736(25)02219-6","tag_type":"warning","value":"Potential impact fractions are modeled from adjusted hazard ratios rather than trial outcomes.","value_numeric":null}],"summaries":{"what_studied":"An individual participant data meta-analysis of device-measured activity from seven prospective cohorts in Norway, Sweden, and the USA (n=40,327; 4,895 deaths), with the UK Biobank analysed separately (n=94,719; 3,487 deaths), estimating the proportion of deaths preventable by small daily increases in MVPA (5–10 min) and reductions in sedentary time (30–60 min) using high-risk (~20% least active) and population-based (all except ~20% most active) approaches.","key_result":"In the main cohorts, adding 5 min/day of MVPA might prevent 6.0% (95% CI 4.3–7.4) of deaths in the least active and 10.0% (6.3–13.4) in all except the most active; reducing sedentary time by 30 min/day might prevent 3.0% (2.0–4.1) and 7.3% (4.8–9.6) of deaths, respectively. In UK Biobank, reducing sedentary time by 30 min/day in all except the most active was associated with preventing 4.5% (2.8–6.1) of deaths.","practice_takeaway":"Encourage small, realistic changes: add about 5 minutes of MVPA per day and cut sitting by about 30 minutes per day; these shifts were associated with preventing roughly 3–10% of deaths across risk-targeted and population-wide scenarios in device-measured cohorts."}},{"doi":"10.1001/jamaoncol.2025.4800","pmid":"41264309","title":"Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2025-11-20T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12635924/","source_score":150,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1001/jamaoncol.2025.4800","days":"7","issn":"2374-2437","rank":"5","field":"Clinical Medicine","score":"150","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1001/jamaoncol.2025.4800","title":"Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.","journal":"JAMA oncology","methods":"","results":"The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer-specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively.","abstract":"$31","keywords":[],"pubmed_id":"41264309","conclusions":"","publication_date":"2025-11-20T00:00:00"},"crossref":{"DOI":"10.1001/jamaoncol.2025.4800","URL":"https://doi.org/10.1001/jamaoncol.2025.4800","ISSN":["2374-2437"],"link":[{"URL":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2841671/jamaoncology_zaorsky_2025_oi_250070_1767385906.3982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"58","type":"journal-article","issue":"1","score":1,"title":["Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer"],"author":[{"given":"Nicholas G.","family":"Zaorsky","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Abdenour","family":"Nabid","sequence":"additional","affiliation":[{"name":"Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto Investigación Sanitaria, Madrid, Spain"}]},{"given":"Michel","family":"Bolla","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, CHU Grenoble, Grenoble, France"}]},{"given":"David","family":"Joseph","sequence":"additional","affiliation":[{"name":"University of Western Australia, Australia"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[{"name":"Sorbonne University, Paris, France"}]},{"given":"Araceli","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Hospital Son Espases, Illes Balears, Spain"}]},{"given":"Ana Alvarez","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Marañón, Madrid, Spain"}]},{"given":"Carmen Gonzalez","family":"San-Segundo","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Marañón, Madrid, Spain"}]},{"given":"Maria Ángeles","family":"Cabeza Rodríguez","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain"}]},{"given":"Josep Maria","family":"Sole","sequence":"additional","affiliation":[{"name":"Hospital Universitari Terrassa, Terrassa, Spain"}]},{"given":"Agustí Pedro","family":"Olivé","sequence":"additional","affiliation":[{"name":"Hospital Plató, Barcelona, Spain"}]},{"given":"Allison","family":"Steigler","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, Quebec, Canada"}]},{"given":"Nathalie","family":"Carrier","sequence":"additional","affiliation":[{"name":"Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada"}]},{"given":"John G.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"St Luke’s Radiation Oncology Network and Cancer Trials, Dublin, Ireland"}]},{"given":"Charles","family":"Gillham","sequence":"additional","affiliation":[{"name":"St Luke’s Radiation Oncology Network and Cancer Trials, Dublin, Ireland"}]},{"given":"Thomas M.","family":"Pisansky","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}]},{"given":"Matthew","family":"Schipper","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[{"name":"Cedars Sinai Medical Center, Los Angeles, California"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}]},{"given":"Colleen","family":"Lawton","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical College of Wisconsin Clinical Cancer Center, Milwaukee"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[{"name":"University College of London, London, England"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rush University, Chicago, Illinois"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}]},{"given":"Shawn","family":"Malone","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical College of Wisconsin Clinical Cancer Center, Milwaukee"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts"}]},{"given":"Jonathan E.","family":"Shoag","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Randy A.","family":"Vince","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Adam","family":"Calaway","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Prateek","family":"Mendiratta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Jason R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Luca","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}]},{"given":"Matthew","family":"Rettig","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Urology, University of California, Los Angeles"},{"name":"Department of Medicine, VA Greater Los Angeles, Los Angeles, California"}]},{"given":"Robert T.","family":"Dess","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}]},{"given":"William C.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}]},{"given":"Ting","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle"}]},{"given":"Angela Y.","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]},{"given":"Michael","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}]},{"given":"Tahmineh","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio"}]}],"issued":{"date-parts":[[2026,1,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"12","created":{"date-time":"2025-11-20T16:01:24Z","timestamp":1763654484000,"date-parts":[[2025,11,20]]},"indexed":{"date-time":"2026-01-16T10:15:57Z","timestamp":1768558557636,"date-parts":[[2026,1,16]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2841671"}},"subtitle":["A Meta-Analysis"],"deposited":{"date-time":"2026-01-15T16:01:20Z","timestamp":1768492880000,"date-parts":[[2026,1,15]]},"issn-type":[{"type":"print","value":"2374-2437"}],"published":{"date-parts":[[2026,1,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S1470-2045(21)00705-1","key":"coi250070r1","year":"2022","issue":"2","author":"Kishan","volume":"23","first-page":"304","unstructured":null,"article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.6004/jnccn.2023.0050","key":"coi250070r2","year":"2023","issue":"10","author":"Schaeffer","volume":"21","first-page":"1067","unstructured":null,"article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology.","journal-title":"J Natl Compr Canc Netw","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaoncol.2021.6871","key":"coi250070r3","year":"2022","issue":"3","author":"Kishan","volume":"8","first-page":null,"unstructured":null,"article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts.","journal-title":"JAMA Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1607529","key":"coi250070r4","year":"2017","issue":"5","author":"Shipley","volume":"376","first-page":"417","unstructured":null,"article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer.","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eururo.2014.07.010","key":"coi250070r5","year":"2015","issue":"5","author":"Nguyen","volume":"67","first-page":"825","unstructured":null,"article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them.","journal-title":"Eur Urol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM199707313370502","key":"coi250070r6","year":"1997","issue":"5","author":"Bolla","volume":"337","first-page":"295","unstructured":null,"article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa0810095","key":"coi250070r7","year":"2009","issue":"24","author":"Bolla","volume":"360","first-page":"2516","unstructured":null,"article-title":"Duration of androgen suppression in the treatment of prostate cancer.","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.21.00855","key":"coi250070r8","year":"2021","issue":"27","author":"Bolla","volume":"39","first-page":"3022","unstructured":null,"article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC Trial 22991 in patients with localized intermediate-risk disease.","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(22)00190-5","key":"coi250070r9","year":"2022","issue":"5","author":"Zapatero","volume":"23","first-page":"671","unstructured":null,"article-title":"High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2010.04.065","key":"coi250070r10","year":"2011","issue":"1","author":"Armstrong","volume":"81","first-page":"35","unstructured":null,"article-title":"A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejca.2020.10.023","key":"coi250070r11","year":"2021","issue":null,"author":"Nabid","volume":"143","first-page":"64","unstructured":null,"article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial.","journal-title":"Eur J Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eururo.2018.06.018","key":"coi250070r12","year":"2018","issue":"4","author":"Nabid","volume":"74","first-page":"432","unstructured":null,"article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial.","journal-title":"Eur Urol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(11)70063-8","key":"coi250070r13","year":"2011","issue":"5","author":"Denham","volume":"12","first-page":"451","unstructured":null,"article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(18)30757-5","key":"coi250070r14","year":"2019","issue":"2","author":"Denham","volume":"20","first-page":"267","unstructured":null,"article-title":"Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2007.13.9881","key":"coi250070r15","year":"2008","issue":"4","author":"Roach","volume":"26","first-page":"585","unstructured":null,"article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2017.02.004","key":"coi250070r16","year":"2017","issue":"2","author":"Lawton","volume":"98","first-page":"296","unstructured":null,"article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202.","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2021.08.031","key":"coi250070r17","year":"2022","issue":"2","author":"Jones","volume":"112","first-page":"294","unstructured":null,"article-title":"Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2014.58.0662","key":"coi250070r18","year":"2015","issue":"4","author":"Pisansky","volume":"33","first-page":"332","unstructured":null,"article-title":"Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.l4898","key":"coi250070r19","year":"2019","issue":null,"author":"Sterne","volume":"366","first-page":"l4898","unstructured":null,"article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaoncol.2020.4922","key":"coi250070r20","year":"2020","issue":"12","author":"Dess","volume":"6","first-page":"1912","unstructured":null,"article-title":"Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate.","journal-title":"JAMA Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2020.06.011","key":"coi250070r21","year":"2020","issue":"4","author":"Spratt","volume":"108","first-page":"899","unstructured":null,"article-title":"Absolute versus relative benefit of androgen deprivation therapy for prostate cancer: moving beyond the hazard ratio to personalize therapy.","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2017.74.2940","key":"coi250070r22","year":"2018","issue":"6","author":"Spratt","volume":"36","first-page":"581","unstructured":null,"article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer.","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2016.70.2811","key":"coi250070r23","year":"2017","issue":"18","author":"Spratt","volume":"35","first-page":"1991","unstructured":null,"article-title":"Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41746-022-00613-w","key":"coi250070r24","year":"2022","issue":"1","author":"Esteva","volume":"5","first-page":"71","unstructured":null,"article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.","journal-title":"NPJ Digit Med","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.299.3.289","key":"coi250070r25","year":"2008","issue":"3","author":"D’Amico","volume":"299","first-page":"289","unstructured":null,"article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2020.15083","key":"coi250070r26","year":"2020","issue":"9","author":"Zumsteg","volume":"3","first-page":null,"unstructured":null,"article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial.","journal-title":"JAMA Netw Open","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaoncol.2020.0109","key":"coi250070r27","year":"2020","issue":"5","author":"Dess","volume":"6","first-page":"735","unstructured":null,"article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer.","journal-title":"JAMA Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2016.06.2445","key":"coi250070r28","year":"2016","issue":"2","author":"Zapatero","volume":"96","first-page":"341","unstructured":null,"article-title":"Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial.","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.2967/jnumed.124.268441","key":"coi250070r29","year":"2025","issue":"1","author":"Unterrainer","volume":"66","first-page":"54","unstructured":null,"article-title":"Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET—an international multicenter retrospective study.","journal-title":"J Nucl Med","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Oncology"],"published-print":{"date-parts":[[2026,1,1]]},"reference-count":29,"published-online":null,"references-count":29,"short-container-title":["JAMA Oncol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamaoncol.2025.4800","is_oa":true,"title":"Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer","updated":"2026-01-19T05:56:36+00:00","published_date":"2025-11-20","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12635924/","pmh_id":"oai:pubmedcentral.nih.gov:12635924","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12635924/"}}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"condition","value":"Localized Prostate Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"modality","value":"Androgen Deprivation Therapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"modality","value":"Radiotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"sample_size","value":"n=10266","value_numeric":10266},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"study_design","value":"Individual Participant Data Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"warning","value":"Design label approximated: this was an individual patient data meta-analysis of phase 3 randomized trials.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"warning","value":"Risk-group–specific ‘optimal’ durations were derived from 10-year distant metastasis; the duration for very high-risk disease was undefined.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4800","tag_type":"warning","value":"Summary is based on the abstract; detailed NNT values, adherence, and between-trial heterogeneity were not available in the provided text.","value_numeric":null}],"summaries":{"what_studied":"An individual patient data meta-analysis of 13 randomized phase 3 trials (n=10,266 men) testing radiotherapy alone or with 0–36 months of androgen deprivation therapy (ADT), with a median follow-up of 11.3 years; primary endpoint was overall survival, with secondary endpoints including biochemical recurrence, distant metastasis, prostate cancer–specific mortality, and other-cause mortality.","key_result":"Longer ADT improved distant metastasis, prostate cancer–specific mortality, and overall survival, with diminishing gains beyond about 9–12 months; other-cause mortality rose with prolonged ADT (hazard ratio 1.28, 95% CI 1.09–1.50; P=.002 for 28 vs 0 months). “Optimal” ADT by 10-year distant metastasis was 0 months (1 intermediate-risk factor), 6 months (≥2 intermediate-risk factors), 12 months (NCCN high-risk), and undefined (NCCN very high-risk).","limitations":"Optimal duration for very high-risk disease remained undefined by 10-year distant metastasis. The cohort was predominantly high/very high risk (72%), limiting representation of lower-risk groups.","practice_takeaway":"When combining ADT with definitive radiotherapy, tailor duration by risk: 0 months for one intermediate-risk factor, 6 months for two or more, and about 12 months for NCCN high-risk, recognizing diminishing benefit beyond 9–12 months. Prolonged ADT increases other-cause mortality; balance duration against this risk, and note that the optimal course for very high-risk disease is unresolved."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"study_design","value":"Individual Participant Data Meta-analysis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study Designs","href":"/hub/tag/study_design"},{"name":"Individual Participant Data Meta-analysis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"study_design","hub_tag_value":"Individual Participant Data Meta-analysis"}}}]]

Papers